AQST · Aquestive Therapeutics, Inc.
$4.25
+0.00 (+0.00%)
At close · Aug 14
Market Cap
$533.42M
Shares
125.51M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Daniel Barber | President and Chief Executive Officer | $3,493,559 |
| Lori J. Braender | Corporate Secretary, Former Chief Legal Officer and Chief Compliance Officer\ | $1,348,238 |
| A. Ernest Toth | Chief Financial Officer\ \ | $1,323,547 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Daniel Barber | Chief Executive Officer | $4,181,472 |
| A. Mark Schobel | Chief Innovation and Technology Officer\ | $3,257,284 |
| Lori J. Braender | Chief Legal Officer, Chief Compliance Officer and Corporate Secretary | $1,821,025 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Daniel Barber | Chief Executive Officer | $2,416,088 |
| Lori J. Braender | Chief Legal Officer, Chief Compliance Officer and Corporate Secretary | $1,146,828 |
| A. Mark Schobel | Chief Innovation and Technology Officer\ | $974,056 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Daniel Barber | Chief Executive Officer | $1,326,598 |
| Lori J. Braender | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $935,910 |
| A. Mark Schobel | Chief Innovation and Technology Officer Keith J. Kendall\ \ Former Chief Executive Officer | $810,019 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Keith Kendall | Chief Executive Officer | $2,049,198 |
| Daniel Barber | Chief Executive Officer Lori J. Braender\ Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $1,157,103 |
| A. Ernest Toth | Chief Financial Officer\ | $1,059,642 |
| A. Mark Schobel | Chief Innovation and Technology Officer Keith J. Kendall\ \ Former Chief Executive Officer | $939,261 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| John Maxwell | Chief Financial Officer\ | $1,311,270 |
| Keith Kendall | Chief Executive Officer | $1,290,418 |
| Daniel Barber | Chief Operating Officer | $840,083 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Keith Kendall | Chief Executive Officer | $2,628,576 |
| Daniel Barber | Chief Operating Officer | $1,195,228 |
| John Maxwell | Chief Financial Officer\ | $1,054,123 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Thomas A. Zalewski | Chief Legal Officer and Chief Compliance Officer | Appointed | 2026-03-20 |
| Timothy E. Morris | member of the Compensation Committee | Appointed | 2024-11-07 |
| John S. Cochran | Chair of the Compensation Committee | Appointed | 2024-11-07 |
| Santo J. Costa | member of the Board of Directors | Resigned | 2024-11-07 |
| Cassie Jung | Chief Operating Officer | Appointed | 2024-06-06 |
| Abigail L. Jenkins | Class II director | Appointed | 2024-04-01 |
| Kenneth Truitt, M.D. | Chief Medical Officer | Appointed | 2022-08-10 |
| Timothy E. Morris | Board | Appointed | 2022-08-10 |
| Daniel Barber | President and Chief Executive Officer | Appointed | 2022-07-19 |
| Daniel Barber | Class I Director | Appointed | 2022-05-17 |
| Daniel Barber | President and Chief Executive Officer | Appointed | 2022-05-17 |
| Keith J. Kendall | Board of Directors | Resigned | 2022-05-17 |
| Keith J. Kendall | President and Chief Executive Officer | Resigned | 2022-05-17 |
Key facts
CIK
1398733
CUSIP
03843E104
13F (30d)
179 filings
175 filers
Visit website
Investor relations